Analysis of the Coagulopathy Developed by COVID-19 Infected Patients

Inclusion Criteria: * Patient with SARS-CoV-2 infection entering hospitalization with or without resuscitation * The patient (or their carer) must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: * Pregnant or breastfeeding patient * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Thrombotic events during treatment: flare-up of venous thromboembolism, flare-up of atherothrombosis. * Long-term anticoagulant treatment (anti-vitamin K, direct oral anticoagulant). * Chronic anti-aggregation treatment. * Pre-existing constitutive or acquired known coagulation pathology: hemorrhagic diseases (thrombocytopenia, thrombocytopathy, hemophilia, von Willebrand's disease, hemorrhagiparous factor deficiency), and for thrombophilia (deficits in antithrombin, protein C or S , Factor V Leiden or Prothrombin 20201A mutation).